Comparing angiotensin receptor–neprilysin inhibitors with sodium–glucose cotransporter 2 inhibitors for heart failure with diabetes mellitus

[1]  G. Sinagra,et al.  [ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: what's new?] , 2022, Giornale italiano di cardiologia.

[2]  Chi‐Hang Lee,et al.  Comparing Sacubitril/Valsartan Against Sodium-Glucose Cotransporter 2 Inhibitors in Heart Failure: A Systematic Review and Network Meta-analysis , 2021, Clinical Drug Investigation.

[3]  J. McMurray,et al.  2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. , 2021, European heart journal.

[4]  R. Pontremoli,et al.  Renal protection in chronic heart failure: focus on sacubitril/valsartan , 2021, European heart journal. Cardiovascular pharmacotherapy.

[5]  L. Køber,et al.  Associations of Empagliflozin With Left Ventricular Volumes, Mass, and Function in Patients With Heart Failure and Reduced Ejection Fraction: A Substudy of the Empire HF Randomized Clinical Trial. , 2021, JAMA cardiology.

[6]  M. Emdin,et al.  Relative Efficacy of Sacubitril-Valsartan, Vericiguat, and SGLT2 Inhibitors in Heart Failure with Reduced Ejection Fraction: a Systematic Review and Network Meta-Analysis , 2020, Cardiovascular Drugs and Therapy.

[7]  Akshay S. Desai,et al.  Efficacy of Dapagliflozin on Renal Function and Outcomes in Patients With Heart Failure With Reduced Ejection Fraction , 2020, Circulation.

[8]  K. Node,et al.  Cardiovascular and renal effectiveness of empagliflozin in routine care in East Asia: Results from the EMPRISE East Asia study , 2020, Endocrinology, diabetes & metabolism.

[9]  A. Mortara,et al.  Renal protection: a leading mechanism for cardiovascular benefit in patients treated with SGLT2 inhibitors , 2020, Heart Failure Reviews.

[10]  P. Ponikowski,et al.  Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure. , 2020, The New England journal of medicine.

[11]  Xiaoting Zhang,et al.  Effects of sacubitril/valsartan in patients with heart failure and chronic kidney disease: A meta-analysis. , 2020, European journal of pharmacology.

[12]  Changjiang Zhang,et al.  SGLT2i: beyond the glucose-lowering effect , 2020, Cardiovascular Diabetology.

[13]  P. Donnan,et al.  Dapagliflozin Versus Placebo on Left Ventricular Remodeling in Patients With Diabetes and Heart Failure: The REFORM Trial , 2020, Diabetes Care.

[14]  Akshay S. Desai,et al.  Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. , 2019, The New England journal of medicine.

[15]  S. Solomon,et al.  Association of Change in N-Terminal Pro-B-Type Natriuretic Peptide Following Initiation of Sacubitril-Valsartan Treatment With Cardiac Structure and Function in Patients With Heart Failure With Reduced Ejection Fraction. , 2019, JAMA.

[16]  Cheuk-Kwan Sun,et al.  The therapeutic impact of entresto on protecting against cardiorenal syndrome-associated renal damage in rats on high protein diet. , 2019, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[17]  Y. Kao Yang,et al.  The Chang Gung Research Database—A multi‐institutional electronic medical records database for real‐world epidemiological studies in Taiwan , 2019, Pharmacoepidemiology and drug safety.

[18]  Deepak L. Bhatt,et al.  Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes , 2019, The New England journal of medicine.

[19]  J. Tamargo.  Sodium–glucose Cotransporter 2 Inhibitors in Heart Failure: Potential Mechanisms of Action, Adverse Effects and Future Developments , 2018, European cardiology.

[20]  J. McMurray,et al.  SGLT2 inhibitors and mechanisms of cardiovascular benefit: a state-of-the-art review , 2018, Diabetologia.

[21]  Akshay S. Desai,et al.  Renal Effects and Associated Outcomes During Angiotensin-Neprilysin Inhibition in Heart Failure. , 2018, JACC. Heart failure.

[22]  R. Guthrie.  Canagliflozin and cardiovascular and renal events in type 2 diabetes , 2018, Postgraduate medicine.

[23]  Wen-Cheng Chen,et al.  Chang Gung Research Database: A multi-institutional database consisting of original medical records , 2017, Biomedical journal.

[24]  G. Filippatos,et al.  Association Between Diabetes and 1-Year Adverse Clinical Outcomes in a Multinational Cohort of Ambulatory Patients With Chronic Heart Failure: Results From the ESC-HFA Heart Failure Long-Term Registry , 2017, Diabetes Care.

[25]  V. Vallon,et al.  Targeting renal glucose reabsorption to treat hyperglycaemia: the pleiotropic effects of SGLT2 inhibition , 2017, Diabetologia.

[26]  J. Langhoff‐Roos.  State‐of‐the‐art review , 2016, Acta obstetricia et gynecologica Scandinavica.

[27]  M. Fischereder,et al.  Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. , 2016, The New England journal of medicine.

[28]  C. Leitão,et al.  Efficacy of SGLT2 inhibitors in glycemic control, weight loss and blood pressure reduction: a systematic review and meta-analysis , 2015, Diabetology & Metabolic Syndrome.

[29]  I. Calderon,et al.  Oxidative DNA damage in diabetic and mild gestational hyperglycemic pregnant women , 2015, Diabetology & Metabolic Syndrome.

[30]  Akshay S. Desai,et al.  Angiotensin-neprilysin inhibition versus enalapril in heart failure. , 2014, The New England journal of medicine.

[31]  Lane F Burgette,et al.  A tutorial on propensity score estimation for multiple treatments using generalized boosted models , 2013, Statistics in medicine.

[32]  Salim Yusuf,et al.  Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. , 1991, The New England journal of medicine.

[33]  Rickham Pp.  Human Experimentation: Code of Ethics of the World Medical Association (Declaration of Helsinki). , 1964, Canadian Medical Association journal.

[34]  K. Swedberg,et al.  Effects of enalapril on mortality in severe congestive heart failure: results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). , 1988, The American journal of cardiology.

[35]  P. P. Rickham.  HUMAN EXPERIMENTATION. CODE OF ETHICS OF THE WORLD MEDICAL ASSOCIATION. DECLARATION OF HELSINKI. , 1964, British medical journal.